AU716514B2 - Use of rapamycin derivatives in vasculopathies and xenotransplantation - Google Patents

Use of rapamycin derivatives in vasculopathies and xenotransplantation Download PDF

Info

Publication number
AU716514B2
AU716514B2 AU22918/97A AU2291897A AU716514B2 AU 716514 B2 AU716514 B2 AU 716514B2 AU 22918/97 A AU22918/97 A AU 22918/97A AU 2291897 A AU2291897 A AU 2291897A AU 716514 B2 AU716514 B2 AU 716514B2
Authority
AU
Australia
Prior art keywords
rapamycin
preventing
ethyl
hydroxy
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU22918/97A
Other languages
English (en)
Other versions
AU2291897A (en
Inventor
Walter Schuler
Hendrik Schuurman
Gisbert Weckbecker
Hans-Gunter Zerwes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU716514(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2291897A publication Critical patent/AU2291897A/en
Application granted granted Critical
Publication of AU716514B2 publication Critical patent/AU716514B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU22918/97A 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation Expired AU716514B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9606452 1996-03-27
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds
PCT/EP1997/001548 WO1997035575A1 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation

Publications (2)

Publication Number Publication Date
AU2291897A AU2291897A (en) 1997-10-17
AU716514B2 true AU716514B2 (en) 2000-02-24

Family

ID=10791127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22918/97A Expired AU716514B2 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation

Country Status (29)

Country Link
US (5) US6384046B1 (enExample)
EP (3) EP1149581A3 (enExample)
JP (2) JP2000507226A (enExample)
KR (2) KR100836971B1 (enExample)
CN (1) CN1124135C (enExample)
AT (1) ATE224194T1 (enExample)
AU (1) AU716514B2 (enExample)
BR (1) BR9708358A (enExample)
CA (1) CA2247275C (enExample)
CY (1) CY2404B1 (enExample)
CZ (1) CZ292483B6 (enExample)
DE (1) DE69715611T2 (enExample)
DK (2) DK2008657T3 (enExample)
ES (2) ES2421455T3 (enExample)
GB (1) GB9606452D0 (enExample)
HU (1) HU226422B1 (enExample)
ID (1) ID17195A (enExample)
IL (1) IL125812A (enExample)
MY (1) MY117798A (enExample)
NO (1) NO316667B1 (enExample)
NZ (1) NZ331463A (enExample)
PL (1) PL187732B1 (enExample)
PT (2) PT893996E (enExample)
RU (1) RU2214247C2 (enExample)
SI (1) SI2008657T1 (enExample)
SK (1) SK284343B6 (enExample)
TR (1) TR199801919T2 (enExample)
WO (1) WO1997035575A1 (enExample)
ZA (1) ZA972719B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
DE69736750T2 (de) 1996-07-30 2007-08-16 Novartis Ag Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
AU4565000A (en) * 1999-05-10 2000-11-21 Novartis Ag Organic compounds
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US7037332B2 (en) 2000-03-15 2006-05-02 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
WO2002026139A1 (en) 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
LT2269604T (lt) 2001-02-19 2016-11-10 Novartis Ag Inkstų solidinių navikų gydymas rapamicino dariniu
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
RU2315621C2 (ru) * 2002-02-22 2008-01-27 Профи Мед Аб Применение ингибитора или антагониста тканевого фактора
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2003099169A1 (en) * 2002-05-20 2003-12-04 Orbus Medical Technologies Inc. Drug eluting implantable medical device
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
TW200605910A (en) * 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20060194829A1 (en) * 2004-12-20 2006-08-31 Clackson Timothy P Therapeutic materials and methods
JP5709354B2 (ja) 2005-11-14 2015-04-30 アリアド・ファーマシューティカルズ・インコーポレイテッド ｍＴＯＲ阻害剤投与によるがん患者の治療
WO2007058399A1 (en) * 2005-11-17 2007-05-24 Access Plus Co., Ltd A tube for connecting marteriovenous and interposition for medical operation
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
EP2431036B1 (en) 2006-09-13 2017-04-12 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US20080103584A1 (en) 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
EP3459572A1 (en) 2007-11-14 2019-03-27 Biosensors International Group, Ltd. Automated coating method
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTONE COMPOUNDS AND METHODS OF USE
US8382818B2 (en) 2009-07-02 2013-02-26 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
KR102323291B1 (ko) 2013-09-24 2021-11-05 기너 라이프 사이언시즈, 인크. 세포 임플란트의 기체 처리를 위한 시스템
EP3738592B1 (en) 2013-10-08 2022-01-26 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP2017505789A (ja) 2014-02-11 2017-02-23 ラム・セラピューティクス，インコーポレーテッド リンパ脈管筋腫症の治療のためのラパマイシン
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
BR112016022598A8 (pt) 2014-04-04 2021-06-29 Ai Therapeutics Inc composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN109689053A (zh) 2016-08-10 2019-04-26 得克萨斯州大学系统董事会 局部雷帕霉素疗法
US12453624B2 (en) 2016-09-19 2025-10-28 Biotronik Ag Polymer-free drug eluting vascular stents
MX2019005676A (es) 2016-11-15 2019-09-10 Giner Life Sciences Inc Dispositivo percutáneo de difusión de gases adecuado para su uso con un implante subcutáneo.
EP3558407B1 (en) 2016-12-22 2023-03-15 Biotronik AG Drug releasing coatings for medical devices and methods of making same
JP7199632B2 (ja) 2017-05-04 2023-01-06 ガイナー，インク． 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
AU2019409366B2 (en) 2018-12-18 2022-10-27 Novartis Ag Rapamycin derivatives
US20200261427A1 (en) 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
KR100284210B1 (ko) * 1992-04-28 2001-03-02 이건 이. 버그 과증식성 혈관 질환 치료용 배합 제제
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
PT734389E (pt) * 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
AU712193B2 (en) * 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
PL187732B1 (pl) 2004-09-30
KR20070083654A (ko) 2007-08-24
HU226422B1 (en) 2008-12-29
JP5124431B2 (ja) 2013-01-23
NZ331463A (en) 2001-10-26
EP0893996A1 (en) 1999-02-03
PL328659A1 (en) 1999-02-15
EP1149581A3 (en) 2003-12-03
CN1214631A (zh) 1999-04-21
US20100152105A1 (en) 2010-06-17
CY2404B1 (en) 2004-09-10
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
DE69715611D1 (de) 2002-10-24
KR20050038656A (ko) 2005-04-27
NO984340D0 (no) 1998-09-18
TR199801919T2 (xx) 1999-02-22
US20120177690A1 (en) 2012-07-12
CA2247275C (en) 2011-10-11
IL125812A0 (en) 1999-04-11
JP2009102349A (ja) 2009-05-14
WO1997035575A1 (en) 1997-10-02
DK2008657T3 (da) 2013-07-22
GB9606452D0 (en) 1996-06-05
EP2008657A3 (en) 2009-02-04
ID17195A (id) 1997-12-11
DK0893996T3 (da) 2002-12-09
EP1149581A2 (en) 2001-10-31
CA2247275A1 (en) 1997-10-02
MY117798A (en) 2004-08-30
EP2008657A2 (en) 2008-12-31
BR9708358A (pt) 1999-08-03
IL125812A (en) 2001-12-23
US20140187574A1 (en) 2014-07-03
DE69715611T2 (de) 2003-05-22
PT2008657E (pt) 2013-07-12
EP0893996B1 (en) 2002-09-18
HUP0001267A2 (hu) 2000-11-28
ES2184078T3 (es) 2003-04-01
CN1124135C (zh) 2003-10-15
US6384046B1 (en) 2002-05-07
SI2008657T1 (sl) 2013-07-31
CZ292483B6 (cs) 2003-09-17
KR100836971B1 (ko) 2008-06-10
JP2000507226A (ja) 2000-06-13
ES2421455T3 (es) 2013-09-02
HUP0001267A3 (en) 2002-01-28
ZA972719B (en) 1998-09-28
HK1018688A1 (en) 1999-12-30
RU2214247C2 (ru) 2003-10-20
ATE224194T1 (de) 2002-10-15
SK284343B6 (sk) 2005-02-04
US20020127248A1 (en) 2002-09-12
SK132798A3 (en) 1999-03-12
EP2008657B1 (en) 2013-04-24
AU2291897A (en) 1997-10-17
CZ307098A3 (cs) 1999-01-13
PT893996E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
AU716514B2 (en) Use of rapamycin derivatives in vasculopathies and xenotransplantation
JP2009102349A6 (ja) 血管疾病および異種移植におけるラパマイシン誘導体の使用
AU728420B2 (en) New use for 1,3-propanediol derivatives
KR100616020B1 (ko) 맥관장애및이종이식술에서의라파마이신유도체의용도
HK1018688B (en) Use of rapamycin derivatives in vasculopqthies and xenotransplantation
HK1022639B (en) New use for 1,3-propanediol derivatives
HK1057469A (en) Use for 1,3-propanediol compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)